Traws Pharma (NASDAQ:TRAW) Posts Quarterly Earnings Results
by Scott Moore · The Cerbat GemTraws Pharma (NASDAQ:TRAW – Get Free Report) issued its earnings results on Wednesday. The company reported ($0.71) EPS for the quarter, FiscalAI reports.
Traws Pharma Price Performance
Traws Pharma stock opened at $1.23 on Thursday. The firm has a 50-day moving average of $1.78 and a 200-day moving average of $2.01. Traws Pharma has a one year low of $0.97 and a one year high of $3.27. The company has a market cap of $9.83 million, a price-to-earnings ratio of 0.01 and a beta of 1.61.
Analyst Ratings Changes
Several analysts have commented on TRAW shares. LADENBURG THALM/SH SH upgraded shares of Traws Pharma to a “strong-buy” rating in a research report on Friday, January 30th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Traws Pharma in a research note on Monday, December 22nd. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Traws Pharma has an average rating of “Moderate Buy” and a consensus target price of $8.00.
Check Out Our Latest Analysis on TRAW
Hedge Funds Weigh In On Traws Pharma
A number of large investors have recently modified their holdings of the business. Seven Fleet Capital Management LP acquired a new position in shares of Traws Pharma during the 4th quarter worth about $56,000. XTX Topco Ltd boosted its stake in shares of Traws Pharma by 294.2% during the 4th quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock worth $48,000 after buying an additional 31,502 shares during the last quarter. Ikarian Capital LLC boosted its stake in shares of Traws Pharma by 2,280.0% during the 4th quarter. Ikarian Capital LLC now owns 678,142 shares of the company’s stock worth $766,000 after buying an additional 649,649 shares during the last quarter. Squadron Capital Management LLC acquired a new position in shares of Traws Pharma during the 4th quarter worth about $806,000. Finally, Boothbay Fund Management LLC acquired a new position in shares of Traws Pharma during the 4th quarter worth about $220,000. 7.95% of the stock is currently owned by institutional investors and hedge funds.
About Traws Pharma
Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.